{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:27Z","timestamp":1792785447793,"version":"4.5.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"received any funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2018,2,1]]},"DOI":"10.1080\/14737140.2018.1421460","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T13:05:22Z","timestamp":1513947922000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["How to use neoadjuvant medical treatment to maximize surgery in melanoma"],"prefix":"10.1080","volume":"18","author":[{"given":"Teresa","family":"Amaral","sequence":"first","affiliation":[{"name":"Center for Dermatooncology, Department of Dermatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Tampouri","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology, Department of Dermatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[{"name":"Center for Dermatooncology, Department of Dermatology, University Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21882"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.306"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1996.01430210073013"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1007\/s10434-999-0633-z"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.136.8.950"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11872"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199812000-00010"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10186"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.9047"},{"key":"CIT0010","unstructured":"Temozolomide alone or with pegylated interferon-Alpha 2b (PGI) in melanoma patients. cited 2017 Apr 5. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT00525031"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp593"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5292"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2498"},{"key":"CIT0014","unstructured":"NAM-Trial: multiferon in malignant melanoma. cited 2017 Apr 5. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01341158"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.010"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.012"},{"key":"CIT0017","volume-title":"Treatment with neoadjuvant + adjuvant dabrafenib and trametinib (D+T) is associated with improved relapse-free survival (RFS) versus standard of care (SOC) therapy in patients with high-risk resectable BRAF-mutant melanoma","author":"Amaria RN","year":"2016"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"CIT0019","unstructured":"Neoadjuvant and adjuvant dabrafenib and trametinib in patients with clinical stage III melanoma (Combi-Neo). cited 2017 May. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02231775"},{"key":"CIT0020","unstructured":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 mutation positive melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01972347"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx377.007"},{"key":"CIT0022","unstructured":"Dabrafenib\/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, melanoma with brain mets,biomarkers and metabolites. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01978236"},{"key":"CIT0023","unstructured":"Study of neo-adjuvant use of vemurafenib plus cobimetinib for BRAF mutant melanoma with palpable lymph node metastases. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02036086"},{"key":"CIT0024","unstructured":"ML29255 neoadjuvant vemurafenib and cobimetinib melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT03005639"},{"key":"CIT0025","unstructured":"Neoadjuvant vemurafenib + cobimetinib in melanoma: NEO-VC. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02303951"},{"key":"CIT0026","unstructured":"Phase 2 study of neoadjuvant vemurafenib in melanoma patients with untreated brain metastases. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/results\/NCT01781026"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3303"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087705"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0081-1"},{"key":"CIT0030","unstructured":"Neoadjuvant and adjuvant checkpoint blockade in patients with clinical stage III or oligometastatic stage IV melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02519322"},{"key":"CIT0031","unstructured":"Optimal neo-adjuvant combination scheme of ipilimumab and nivolumab (OpACIN-neo). cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02977052"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx377.008"},{"key":"CIT0033","unstructured":"Neoadjuvant pembrolizumab for unresectable stage III and unresectable stage IV melanoma (NeoPembroMel). cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/show\/NCT02306850"},{"key":"CIT0034","unstructured":"Neoadjuvant combination biotherapy with pembrolizumab and high dose IFN-alfa2b. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/show\/NCT02339324"},{"key":"CIT0035","unstructured":"Neoadjuvant dabrafenib, trametinib and\/or pembrolizumab in BRAF mutant resectable stage III melanoma (NeoTrio). cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT02858921"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1952-0"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2667"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.tps9094"},{"key":"CIT0039","unstructured":"Neoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) in cutaneous stage L-lll melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02451488"},{"key":"CIT0040","unstructured":"Neoadjuvant L19IL2\/L19TNF- pivotal study (Pivotal). cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/show\/NCT02938299"},{"key":"CIT0041","unstructured":"Effect of rIL-21 on metastases in lymph nodes in melanoma skin cancer. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT00601861"},{"key":"CIT0042","unstructured":"Study of the anti-angiogenesis agent axitinib in patients with stage III malignant melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT01321437"},{"key":"CIT0043","unstructured":"A tissue collection study of pembrolizumab (MK-3475) in subjects with resectable advanced melanoma. cited 2017 Dec 15. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT02434354"},{"key":"CIT0044","unstructured":"Neoadjuvant combination therapy with ipilimumab and highdose IFN-\u03b12b for melanoma. cited 2017 Apr 4. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/study\/NCT01608594"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2018.1421460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T02:07:26Z","timestamp":1598753246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2018.1421460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2,1]]}},"alternative-id":["10.1080\/14737140.2018.1421460"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2018.1421460","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}